How Should a Safe and Effective COVID-19 Vaccine be Allocated? Health Economists Need to be Ready to Take the Baton.
Roope LSJ. et al, (2020), Pharmacoecon Open
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge.
Si L. et al, (2020), Value Health, 23, 1163 - 1170
Patient-reported outcome measures (PROMs): can they be used to guide patient-centered care and optimize outcomes in total knee replacement?
Tew M. et al, (2020), Qual Life Res
Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Badve SV. et al, (2020), N Engl J Med, 382, 2504 - 2513
A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes.
Tran-Duy A. et al, (2020), Diabetes Care
CANCER RISK AND RESOURCE UTILIZATION FOR 5 COMMON CANCERS IN A MATCHED CHINESE DIABETES POPULATION OF 331,000 PATIENTS
Wu N. et al, (2020), VALUE IN HEALTH, 23, S58 - S58
Group Testing for SARS-CoV-2: Forward to the Past?
Pouwels KB. et al, (2020), PharmacoEconomics - Open
Accurately reflecting uncertainty when using patient-level simulation models to extrapolate clinical trial data
DAKIN H. et al, (2020), Medical Decision Making
Registered Reports: Time to Radically Rethink Peer Review in Health Economics
CLARKE P. et al, (2020), PharmacoEconomics - Open
Defining and measuring health poverty
Clarke P. and Erreygers G., (2020), Social Science and Medicine, 244
Exploring the Impact of Quality of Life on Survival: A Case Study in Total Knee Replacement Surgery
Tew M. et al, (2020), Medical Decision Making
Primary Prevention of Cardiovascular Disease in Minority Indigenous Populations: A Systematic Review
Merone L. et al, (2020), Heart Lung and Circulation
The Surgeon's Role in the Opioid Crisis: A Narrative Review and Call to Action.
Shadbolt C. et al, (2020), Front Surg, 7
Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial
Furler J. et al, (2020), The Lancet Diabetes and Endocrinology, 8, 17 - 26
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.
Kent S. et al, (2019), PharmacoEconomics
Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.
Tew M. et al, (2019), Pharmacoeconomics, 37, 931 - 941